GlassScriptPhysician profile
Jefferey D Adair
NPI 1780665828
$4,885.81
in general payments reported to CMS, 2019-2025
27 companies · $707 in 2025
The $707 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,087 · 2020: $1,336 · 2021: $727 · 2022: $423 · 2023: $210 · 2024: $395 · 2025: $707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,312.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $1,621.08 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,290.50 | 2020-2025 | Relistor |
| Daiichi Sankyo INC. | $366.49 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $286.43 | 2019-2020 | |
| Pfizer INC. | $198.37 | 2019-2020 | |
| Biodelivery Sciences International, INC. | $169.91 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $101.17 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $85.67 | 2019-2020 | |
| Amgen INC. | $85.15 | 2021-2022 | |
| Abbvie INC. | $68.94 | 2021-2025 | |
| Vertex Pharmaceuticals Incorporated | $65.83 | 2024-2025 | |
| Arbor Pharmaceuticals, INC. | $62.51 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $60.66 | 2023-2024 | Quviviq |
| Collegium Pharmaceutical, INC. | $54.10 | 2020-2024 | Xtampza, Belbuca |
| Lundbeck LLC | $51.59 | 2024 | Vyepti |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $39.50 | 2019 | |
| Ibsa Pharma INC. | $37.84 | 2022 | |
| Horizon Therapeutics Plc | $37.01 | 2019-2021 | |
| Boston Scientific Corporation | $33.16 | 2019 | |
| Stimwave Technologies Incorporated | $31.19 | 2019-2020 | |
| Redhill Biopharma INC. | $28.06 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $27.00 | 2020 | |
| Lilly USA, LLC | $20.44 | 2023 | Jardiance |
| Almatica Pharma LLC | $17.94 | 2021 | |
| Shionogi INC | $15.53 | 2019 | |
| Tonix Medicines, INC. | $15.02 | 2025 | Tonmya |
| Assertio Therapeutics, INC. | $14.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jefferey Adair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.